Healthcare [ 7/13 ] | Diagnostics & Research [ 58/163 ]
NASDAQ | Common Stock
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer.
The company was incorporated in 2014 and is based in San Antonio, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.26 Decreased by -42.61% | -0.20 Decreased by -28.35% |
| Mar 5, 24 | 0.00 Increased by +100.00% | -0.20 Increased by +100.00% |
| Nov 14, 23 | -0.26 Increased by +55.93% | -0.15 Decreased by -73.33% |
| Aug 14, 23 | -0.20 Decreased by -566.67% | -0.13 Decreased by -53.85% |
| May 15, 23 | -0.18 Increased by +62.50% | -0.21 Increased by +14.29% |
| Mar 31, 23 | -0.19 | -0.19 |
| Nov 14, 22 | -0.59 | - |
| Sep 2, 22 | -0.03 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 2.21 M Increased by +240.22 K% | -2.37 M Decreased by -54.83% | Decreased by -107.22% Increased by +99.94% |
| Dec 31, 23 | 2.21 M Increased by +94.25 K% | -2.37 M Decreased by -41.53% | Decreased by -107.22% Increased by +99.85% |
| Sep 30, 23 | 298.48 K Increased by +25.86 K% | -2.29 M Increased by +53.43% | Decreased by -767.51% Increased by +99.82% |
| Jun 30, 23 | 19.74 K Increased by +1.41 K% | -1.74 M Decreased by -257.09% | Decreased by -8.82 K% Increased by +76.37% |
| Mar 31, 23 | 921.00 Increased by +N/A% | -1.53 M Decreased by -4.13% | Decreased by -166.43 K% Decreased by N/A% |
| Dec 31, 22 | 2.35 K Increased by +N/A% | -1.68 M Increased by +69.93% | Decreased by -71.47 K% Decreased by N/A% |
| Sep 30, 22 | 1.15 K Increased by +N/A% | -4.92 M Decreased by -224.98% | Decreased by -427.78 K% Decreased by N/A% |
| Jun 30, 22 | 1.31 K Increased by +N/A% | -487.32 K Decreased by -132.92% | Decreased by -37.31 K% Decreased by N/A% |